- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Progressive fibrosing interstitial lung disease (PF-ILD)
- Meeting Date: September 2021
- Public Summary Document (PSD) September 2021 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) September 2021 PBAC Meeting - (Word 465KB)
Nintedanib – September 2021
Nintedanib: Capsule 100 mg, Capsule 150 mg; Ofev®
Last updated
24 December 2021